WAVEMAN · COMPANY
ONMD · Onemednet Corp
> Ask across 15+ datasets ⌘K
LIVE
TEAM-2.53% 13F +439META-3.33% 13F +2,704RCG+0.33% CLUSTERUTHR+0.69% 13F +427CRWV-2.82% 13F +695CRM-1.76% 13F +1,024CVNA+1.37% 13F +799DELL+5.01% 13F +1,208TPL+0.83% 13F +443NET-2.73% 13F +713MSTR-1.86% 13F +525CRWD-2.90% 13F +1,385ANET+0.41% 13F +1,327COIN-2.06% 13F +475TEAM-2.53% 13F +439META-3.33% 13F +2,704RCG+0.33% CLUSTERUTHR+0.69% 13F +427CRWV-2.82% 13F +695CRM-1.76% 13F +1,024CVNA+1.37% 13F +799DELL+5.01% 13F +1,208TPL+0.83% 13F +443NET-2.73% 13F +713MSTR-1.86% 13F +525CRWD-2.90% 13F +1,385ANET+0.41% 13F +1,327COIN-2.06% 13F +475
← ALL COMPANIES

ONMD

OneMedNet Corp
PHARMA & BIOTECH · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · CIK 0001849380
Quote by TradingView
CLUSTER · 3 INSIDERSC-SUITE BUYING · 2☆ WATCH
INSIDER NET · 180D
$2.7M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
3
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
+111.4%
XBRL, annual
NET MARGIN
-206.1%
RATIOS · FROM THE COMPANY'S OWN XBRL FILINGS · LATEST FILINGS
REVENUE, TTM
$1.3M
four quarters, 2025-04-01 to 2026-03-31
Yearly / quarterly
FY Dec 2025$1.4M
FY Dec 2024$643.0K
FY Dec 2023n/a
FY Dec 2022n/a
Mar 2026$96.0K
Dec 2025$891.0K
Sep 2025$177.0K
Jun 2025$155.0K
Mar 2025$137.0K
Dec 2024$26.0K
Sep 2024$142.0K
Jun 2024$227.0K
at each fiscal year end
single quarter
NET MARGIN, TTM
-254.1%
net income over revenue, 2025-04-01 to 2026-03-31
Yearly / quarterly
FY Dec 2025-206.0%
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
Mar 2026n/a
Dec 2025-352.4%
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
at each fiscal year end
single quarter
FREE CASH FLOW, TTM
-$7.2M
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Yearly / quarterly
FY Dec 2025-$7.5M
FY Dec 2024-$7.0M
FY Dec 2023n/a
FY Dec 2022n/a
Mar 2026-$1.5M
Dec 2025-$1.7M
Sep 2025-$1.6M
Jun 2025-$2.4M
Mar 2025-$1.9M
Dec 2024-$2.0M
Sep 2024-$1.9M
Jun 2024-$1.5M
at each fiscal year end
single quarter
DEBT TO EQUITY
n/a
equity is zero or negative, the ratio has no meaning
Yearly / quarterly
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
at each fiscal year end
trailing four quarters at each quarter end
CASH FLOW TO DEBT
-40.86x
TTM operating cash flow over long-term debt only, 2026-03-31
Yearly / quarterly
FY Dec 2025-34.10x
FY Dec 2024-3.00x
FY Dec 2023-10.30x
FY Dec 2022n/a
Mar 2026-40.86x
Dec 2025-34.10x
Sep 2025-3.34x
Jun 2025-3.49x
Mar 2025-3.11x
Dec 2024-3.00x
Sep 2024-2.90x
Jun 2024-2.46x
at each fiscal year end
trailing four quarters at each quarter end
RETURN ON EQUITY
n/a
average equity is zero or negative
Yearly / quarterly
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
at each fiscal year end
trailing four quarters at each quarter end
RETURN ON ASSETS
-207.0%
TTM net income over average of 2025-03-31 and 2026-03-31
Yearly / quarterly
FY Dec 2025-95.3%
FY Dec 2024-483.4%
FY Dec 2023-3,854%
FY Dec 2022n/a
Mar 2026-207.0%
Dec 2025-95.3%
Sep 2025-69.0%
Jun 2025-198.4%
Mar 2025-799.5%
Dec 2024-483.4%
Sep 2024-282.5%
Jun 2024-142.0%
at each fiscal year end
trailing four quarters at each quarter end
RETURN ON INVESTED CAPITAL
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Yearly / quarterly
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
at each fiscal year end
trailing four quarters at each quarter end
RETURN ON CAPITAL EMPLOYED
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Yearly / quarterly
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024-187.9%
at each fiscal year end
trailing four quarters at each quarter end
P/E, TRAILING
n/a
trailing loss, a multiple of a loss is not meaningful
Yearly / quarterly
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 20240.23x
Jun 2024n/a
at each fiscal year end
trailing four quarters at each quarter end
ENTERPRISE VALUE
$35.3M
market value at close 2026-09-25 on 2026-05-12 shares, plus long-term debt only, 2026-03-31, minus cash 2026-03-31
Yearly / quarterly
FY Dec 2025$55.7M
FY Dec 2024$40.2M
FY Dec 2023$26.6M
FY Dec 2022n/a
Mar 2026$44.3M
Dec 2025$55.7M
Sep 2025$52.4M
Jun 2025$19.6M
Mar 2025$18.8M
Dec 2024$40.2M
Sep 2024$14.9M
Jun 2024$25.4M
at each fiscal year end
trailing four quarters at each quarter end
FCF YIELD
-20.4%
TTM free cash flow over market value at close 2026-09-25
Yearly / quarterly
FY Dec 2025-13.4%
FY Dec 2024-18.4%
FY Dec 2023n/a
FY Dec 2022n/a
Mar 2026-16.2%
Dec 2025-13.4%
Sep 2025-15.6%
Jun 2025-47.0%
Mar 2025-44.0%
Dec 2024-18.4%
Sep 2024-46.1%
Jun 2024-25.3%
at each fiscal year end
trailing four quarters at each quarter end
PEG, TRAILING
n/a
trailing loss, a multiple of a loss is not meaningful
Yearly / quarterly
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
at each fiscal year end
trailing four quarters at each quarter end
TTM = FOUR CONSECUTIVE FISCAL QUARTERS, Q4 DERIVED AS YEAR MINUS NINE MONTHS WHEN NOT FILED · RETURNS ON AVERAGE OPENING AND CLOSING BALANCES · EBIT APPROXIMATED BY OPERATING INCOME · PEG ON TRAILING EPS GROWTH · PRICE AS OF 2026-09-25 · HOVER A YEARLY OR QUARTERLY LINE FOR WHAT IT WAS COMPUTED FROM

WaveMan Stock Sonar 4/7 axesFind similar shapesCompare

ONMD ranks highest on insider conviction (90th percentile) and growth (85th), and lowest on financial health (14th), among Pharma & Biotech peers.

Financial health
14
inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-40.86x · 14 pct, sector of 371
Growth
85
inputs
  • Revenue growth, YoY+111.4% · 85 pct, sector of 507
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
90
inputs
  • Net open-market buying, 180d$2.7M · 92 pct, sector of 441
  • Insider buyers, 180d3 · 89 pct, sector of 446
Risk and compliance
75
inputs
  • Short interest, % of shares outstanding (no float on file)+1.7% · 75 pct, sector of 815
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Profitability, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; the filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored, each a percentile against sector peers (universe where the sector is thin). Higher is better on every axis; an unscored axis is unmeasured, not a low score. How it is scored

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$2.7M over 180 days
+$1.1M over 90 days · +$2.6M of it by a 10%+ holder
more than 92% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
+111.4% year over year
more than 85% of Pharma & Biotech
MARGIN
-206.1% net margin
below 66% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
1.7% of shares outstanding short · 4.7 days to cover · settled 2026-09-15
below 67% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
3 insiders independently bought a net $2.7M while the stock fell 27% over six months, no planned sales are queued against it.

Watch ONMD

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Email me when insiders trade ONMD
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date, hover any marker for the detail
TOTAL 12M RETURN -29.3%
-29.3%12M
-46%+50%+146%+241%2025-092025-112026-012026-032026-052026-072026-09 2026-07-30 · Kosasa Thomas bought $1,000.0K2026-04-01 · Yu Jeffrey bought $750.0K2026-02-06 · Kosasa Thomas bought $500.0K2026-05-18 · Kosasa Thomas bought $250.0K2026-04-23 · Kosasa Thomas bought $250.0K2025-10-22 · Green Aaron sold $144.4K2026-06-16 · Yu Jeffrey bought $100.0K2026-06-23 · Yu Jeffrey bought $100.0K2026-06-12 · Kosasa Thomas bought $100.0K2026-09-10 · Yu Jeffrey bought $90.0K2025-11-18 · Green Aaron sold $73.9K2025-10-15 · Casaburi Eric bought $30.5K2026-06-23 · Green Aaron bought $20.9K2026-06-12 · Green Aaron bought $20.7K2025-09-24 · Yu Jeffrey bought $17.5K2026-06-15 · Green Aaron bought $10.1K2025-09-24 · Kosasa Thomas bought $5.6K2025-09-23 · Yu Jeffrey bought $5.3K2025-09-25 · Yu Jeffrey bought $1.3K
INSIDER BUYINSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED, NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence , no filings are marked on this one
WHY THIS NAME IS ON THE DESK
3 insiders reported buying shares.
The record shows a net $2.7M bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLINSM
Insider transactions
Form 4 purchases and sales (codes P and S), grants, option exercises and preferred conversions excluded

Over the last 180 days, OneMedNet Corp insiders bought a net $2.7M of stock across 88 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-28.

INSIDER
FILED
SHARES
VALUE
Yu Jeffrey
Chief Medical Officer
BUY
2026-09-10
142,857
$90.0K
Kosasa Thomas
Director
BUY
2026-07-30
1,449,275
$1,000.0K
Green Aaron
Chief Executive Officer
BUY
2026-06-23
36,650
$20.9K
Yu Jeffrey
Chief Medical Officer
BUY
2026-06-23
158,730
$100.0K
Yu Jeffrey
Chief Medical Officer
BUY
2026-06-16
172,414
$100.0K
88 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 83 more transactions on record, and use the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then, restatements and all
2025-122024-122023-122022-12
REVENUE$1.4M$643.0K$1.0M$1.2M
GROSS PROFIT$-503.0K$-281.0K$-129.0K$-360.0K
OPERATING INCOME$-9.7M$-9.6M$-6.9M$-7.7M
NET INCOME$-2.8M$-10.1M$-33.8M$-30.5M
EPS (DILUTED)-0.06-0.36-4.65-7.66
OPERATING CASH FLOW$-7.5M$-7.0M$-4.8M$-4.7M
CASH$585.0K$172.0K$47.0K$271.0K
LONG-TERM DEBT$220.0K$2.3M$465.0K,
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-28 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE